AzTrials
AzTrials

Pain ManagementNCT06488183

Laparoscopic Preperitoneal Local Anesthetic Infiltration Versus Ultrasound Guided Quadratus Lumborum Block in Laparoscopic Bariatric Surgery

A study testing preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q in people with Pain Management, run by sarah mohamed at 1 site in Egypt.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

preperitoneal local anesthetic infiltration is effective for relief of postoperative pain in patients undergoing laparoscopic bariatric surgery. Read more about this study

Who is it for?
Ages 20 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Pain Management
What is being tested?
preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
44 participants
Where
1 siteEgypt
Study dates
12 May 2024to Aug 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Age: 20-50 years, both sexes.
  • ASA physical status class I to III.
  • BMI 35-50 kg/m²

Who cannot join

  • Severe cardiac disorder
  • chronic renal failure
  • liver cirrhosis
  • allergy to bupivacaine
  • patients with history of chronic opioid consumption
  • HBA1C > 7%

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

sarah m elgamal, MD contact

01005496440

sarahelgamal1990@yahoo.com

Egypt1 site, 1 recruiting
  • Alexandria University

    Alexandria

    sarah m elgamal, MD, 01005496440, sarahelgamal1990@yahoo.com

    sarah m elgamal, MD

    Recruiting

Other trials in Egypt

About this study

preperitoneal local anesthetic infiltration is effective for relief of postoperative pain in patients undergoing laparoscopic bariatric surgery.

Read the detailed description

Obesity and overweight have become a global epidemic, impacting people of all ages and socioeconomic status. Obesity is still a major public health issue globally, despite progress in some places. Bariatric surgery remains the most effective and long-lasting way to lose weight and address obesity-related conditions.(1) Optimizing postoperative pain treatment is crucial for reducing complications, shortening hospital stays, and lowering expenditures in patients undergoing surgery. Multimodal analgesia and postoperative pain reduction are especially relevant to bariatric surgery patients, who frequently have numerous coexisting conditions and are more vulnerable to thrombotic and respiratory problems. Obstructive sleep apnea (OSA) is common among obese individuals, making safe analgesic treatment problematic. Controlling pain following bariatric surgery is particularly difficult. General management recommendations include multimodal analgesic therapy, regional methods, avoidance of sedatives and early mobilization.(2, 3, 4, 5)

Blanco originally described the quadratus lumborum block (QLB) in 2007. The primary benefit of QLB is the extension of a local anesthetic agent beyond the transversus abdominis plane into the thoracic paravertebral area. The greater distribution of local anesthetic agents may provide significant analgesia and prolong the action of the injected local anesthetic solution.(6)

Preperitoneal local anesthetic injection was initially developed by Dean et al. as a pain management strategy for laparoscopic hernia repair, and it is currently widely used.(7) A recent meta-analysis compared preperitoneal and subcutaneous wound catheters to epidural analgesia. Preperitoneal wound catheters were shown to be as effective as epidural analgesia in abdominal surgeries. Periportal wound catheters appear to be more effective in terms of patient satisfaction and recovery.(8) A recent study concluded that preperitoneal local anesthetic infiltration is effective for relief of postoperative pain in patients undergoing laparoscopic bariatric surgery.(9)

Aim of the work:

The present study aims to compare the analgesic efficacy of ultrasound-guided trans-muscular quadratus lumborum block (QLB) to preperitoneal local anesthetic infiltration during laparoscopic bariatric surgery and in the early postoperative period.

Primary outcome:

  • Postoperative pain score

Secondary outcomes:

  • Intraoperative fentanyl requirements
  • Postoperative morphine requirements
  • Time to first dose of rescue analgesia
  • Postoperative nausea and vomiting
  • Length of stay in PACU
  • Early mobilization
  • Length of hospital stay

Patients :

Study settings:

This study will be conducted in general surgery department, Alexandria university hospitals.

Study design:

Double blind, randomized, prospective and controlled study

Sample size calculation:

Based on previous study(10, 11), we would need a minimum sample size of 44 participants (22 in each group) to reliably detect an effect size of δ≥ 0.883, assuming a two-sided criterion for detection that allows for a maximum type I error rate of a= 0.05 that achieve 80% power.

Table 1 - Sample Size and Power Analysis User Defined Group P LPLAI Group Q QLB Effect Size Power α 22 22 0.883 0.800 0.0500

The power analysis of sample size (22) in this study equals 0.80, this indicates there is an 80% probability that the statistical test used in our study will correctly reject the null hypothesis.

Study population:

All patients will be randomized 1:1 using a sealed envelope method. Patients will be divided into two equal groups:

Group Q: patients will undergo laparoscopic bariatric surgery under general anesthesia and bilateral ultrasound guided quadratus lamborum block (QLB).

Group P: patients will undergo laparoscopic bariatric surgery under general anesthesia and preincisional laparoscopic preperitoneal bupivacaine infiltration.

Inclusion criteria:

  1. Age: 20-50 years, both sexes.
  2. ASA physical status class I to III.
  3. BMI 35-50 kg/m²

Exclusion criteria:

  1. Severe cardiac disorder
  2. chronic renal failure
  3. liver cirrhosis
  4. allergy to bupivacaine
  5. patients with history of chronic opioid consumption
  6. HBA1C > 7%

Methods:

Preoperative evaluation and preparation:

During preoperative visit, evaluation of patients will be carried out through proper history taking, clinical examination and routine laboratory investigations including complete blood picture, coagulation profile, blood urea, serum creatinine, serum electrolytes, fasting blood glucose, glycosylated haemoglobin (HBA1C), liver function tests and any other investigation needed.

Pre-anesthetic preparation and premedication:

  • Informed written consent, from all individual participants who will be included in this study will be taken during preoperative visit.
  • Patients should be trained during preoperative visit on a visual analogue scale (VAS), with 0 corresponding to no pain and 10 to the worst pain imaginable.
  • Patients will be informed about the analgesic regimen
  • Thrombotic prophylaxis (enoxaparin 40 mg) will be started 12 hours before surgery.

On arrival to operative theatre, intravenous cannula will be inserted and standard monitoring will be established using multichannel monitor (Carescape Monitor B650, GE Healthcare Finland) to monitor the following in both groups:

  • Electrocardiogram (ECG) for heart rate and rhythm. (Beats/min).
  • Non-invasive measurement of arterial blood pressure. (Mean blood pressure in mmHg).
  • Pulse oxygen saturation. (SpO2%).
  • End tidal CO2 tension (in mmHg).
  • Entropy

Anesthesia:

After preoxygenation for 3 minutes, anesthesia will be induced in both groups with propofol 2mg/kg of lean body weight until loss of verbal response, fentanyl 2µg/kg and atracurium 0.5 mg/kg intravenously. Anesthesia will be maintained by isoflurane with 50% oxygen in air (1.2-1.5 %) to maintain entropy between 40-60. Mechanical ventilation will be performed with tidal volume of 8 ml/ kg and a respiratory rate of 12-15 cycles/min to maintain the end-tidal carbon dioxide tension between 35 and 40 mmHg and an oxygen saturation of ≥ 98 per cent with 50 percent oxygen in air. Incremental doses of atracurium will be given every 30 minutes to maintain muscle relaxation. In both groups, signs of insufficient analgesia (eg, tachycardia over 20% of the preoperative value occur during anesthesia) or somatic response (eg, movement ,tearing ,or sweating), will be treated with additional boluses of fentanyl 0.5 mcg/kg intraoperatively as needed. Intraoperatively, all patients will receive IV dexamethasone (8 mg), paracetamol (1 g), ketorolac (30 mg).

All patients in group Q will receive bilateral injection of 30ml bupivicaine 0.25% between quadratus lumborum and psoas major muscles after induction of general anesthesia. Patients in group P will receive 60 ml bupivacaine 0.25% in the preperitoneal space from all quadrants around each trocar and will be held in trendeleberg's position for 5 minutes.

Technique of ultrasound guided quadradus lumborum block:(12) The patient will be placed in the lateral position with the side to be anesthetized turned upwards. Skin preparation with povidone iodine solution will be done, and curvilinear transducer will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then the transducer will be moved dorsally keeping the transverse orientation until the quadratus lumborum muscle will be identified with its attachment to the lateral edge of the transverse process of the L4 vertebral body. The needle will be inserted in-plane to the transducer and advanced till penetrating the ventral proper fascia of the quadratus lumborum muscle and 30 ml bupivacaine 0.25% will be injected between the quadratus lumborum and psoas major. The procedure will be repeated on the opposite side.

Technique of laparoscopic preperitoneal local anesthetic infiltration:(10) The patient will be placed in the supine position on the bed with both arms secured to the footboard. Pneumoperitoneum will be achieved via a Veress needle at the Palmer's point. A camera incision will be made 16 cm from the xiphoid process and 1 cm to the left midline. An 11mm port trocar was inserted; a 5mm camera size will be used to explore the abdomen. With the guidance of the camera, the second skin incision will be made for 15mm port, 1 cm proximal, and 5 cm to the right of the first incision. The third incision (5mm) will be made 1 cm proximal and 5 cm to the left side of the patient. The fourth incision (5mm) will be made 1 - 3 cm to the left of the xiphoid process. After skin incisions were made, a Veress needle will be inserted until it reach the preperitoneal space under laparoscopic guidelines with infiltration of 60 ml of bupivacaine 0.25% . The periperitoneum space will be infiltrated adequately from all the quadrants around each trocar. Only the camera port will be infiltrated after the trocar placement. The infiltration takes 20 - 30 seconds for each port.

At the end of surgery, awake extubation, in a semi-sitting position, will be done. Then, the patient will be transferred to the PACU. In PACU, all patients will be assessed for presence and severity of pain; using Visual Analog Scale (VAS). Patients will be prescribed IV morphine 0.1 mg/kg of lean body weight boluses on 4-6 hours basis with a maximum of 10 mg if VAS > 3. Pain control in the ward will be achieved with IV paracetamol 1 g every 6 hours and ketorolac 30 mg every 12 hours. Outcome assessors in PACU and ward will be blinded to patient group assignment and to the nature of the study.

Measurements:

The following data will be measured:

I- Demographic data:

Patient's age (years), sex, body mass index (BMI) (kg/m2 ) and co-morbidities will be recorded.

II- Haemodynamic measurements:

  • Pulse rate (Beat / min).
  • Non-invasive measurement of mean arterial blood pressure (in mmHg)
  • Pulse oxygen saturation All previous parameters will be continuously monitored and recorded before induction of anesthesia, after anesthesia and every 30 minutes until end of surgery.

III- Intraoperative fentanyl requirements (mcg). IV- length of stay in PACU (minutes). V- Assessment of pain using VAS at 1, 2, 4, 6, 12 and 24 hours postoperatively. VI- Time to first morphine dose. VII- Postoperative morphine requirements (mg) VIII- Postoperative nausea and vomiting IX- length of hospital stay (days).

Conditions
Pain Management
Being tested
preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
Keywords
preperitoneal infiltration , bariatric surgery
Medical subject headings
Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group QProcedure or surgery

    preperitoneal local anesthetic infiltration in group p quadratus lamborum block in group Q

Study groups in NCT06488183
Study groupRoleWhat they receive
group pOtherlaparoscopic preperitoneal local anesthetic infiltration
Receives: Procedure: preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q
group QOtherultrasound guided quadratus lamborum block
Receives: Procedure: preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. postoperative pain score

    VAS score

    Measured: postoperative day 1

Secondary outcomes (4)
  1. postoperative morphine requirements

    mg

    Measured: postoperative day 1

  2. postoperative nausea and vomiting

    number

    Measured: postoperative day1

  3. length of stay in pacu

    minutes

    Measured: postoperative day 1

  4. Length of hospital stay

    days

    Measured: postoperative day 3

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jul 2024
  2. Study start12 May 2024
  3. Primary completionAug 2025 (estimated)
  4. Study completionAug 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
44 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06488183
Sponsor's protocol ID
0306673
Status last verified
Jan 2025
First submitted
28 Jun 2024
Last updated
29 Jan 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Aldohayan A, Alshammari S, Binjaloud A, Bamehriz F, Narejo AS, Aqil M, Aldahian N, Aldabaeab A, Eldawlatly A. Pre-incisional Laparoscopic Preperitoneal Local Anesthetic Technique in Laparoscopic Sleeve Gastrectomy. JSLS. 2022 Jul-Sep;26(3):e2022.00049. doi: 10.4293/JSLS.2022.00049.

    PubMed 36071990

Questions about this trial

What is this clinical trial studying?

A study testing preperitoneal local anesthetic infiltration in group p , quadratus lamborum block in group Q in people with Pain Management, run by sarah mohamed at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact sarah m elgamal, MD (01005496440, sarahelgamal1990@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

postoperative pain score (time frame: postoperative day 1). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06488183, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in